pre-IPO PHARMA
COMPANIES VC JOBS NEWS CONTACT

agilis-biotherapeutics PRESS RELEASE ARCHIVE

Aug 23, 2018

PTC Therapeutics Successfully Completes Acquisition of Agilis Biotherapeutics

May 16, 2018

Agilis Biotherapeutics Conducts a Scientific Symposium for Education and Awareness of AADC Deficiency at the 21st Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT)

May 14, 2018

Agilis Biotherapeutics Announces Data Presentations on AADC Deficiency at the American Society of Gene and Cell Therapy 2018 Annual Meeting

May 2, 2018

Agilis Biotherapeutics Presents on Gene Therapy Pricing Strategies at the 2nd Annual Gene Therapy for Rare Disorders Summit

Apr 24, 2018

Agilis Biotherapeutics Presents Platform Paper on AADC Deficiency Gene Therapy at American Academy of Neurology Annual Meeting

Jan 5, 2018

Agilis Biotherapeutics to Present at 36th Annual J.P. Morgan Healthcare Conference

Oct 31, 2017

Agilis Biotherapeutics Announces Orphan Product Designation Approval in Europe for the Treatment of Friedreich Ataxia

Oct 20, 2017

Agilis Biotherapeutics Announces Presentations on Angelman Syndrome Program at ESGCT and NORD Rare Disease Summit

Oct 3, 2017

Agilis Biotherapeutics Updates on Progress in CNS Gene Therapy Programs

Sep 6, 2017

Agilis Biotherapeutics Updates Progress of its CNS Gene Therapy for AADC Deficiency

Aug 2, 2017

Agilis Biotherapeutics and Gene Therapy Research Institution Enter into Strategic Partnership

May 10, 2017

Agilis Biotherapeutics Announces Presentation of Data from Phase I/II Trial for Treatment of AADC Deficiency

May 8, 2017

Agilis Biotherapeutics Expands Commercial, Medical Teams

Dec 1, 2016

Agilis Biotherapeutics Announces Orphan Designation Approval in Europe for the Treatment of AADC Deficiency

Nov 17, 2016

Agilis Biotherapeutics Achieves FDA “Rare Pediatric Disease” Designation for AADC Gene Therapy Candidate

Oct 11, 2016

Agilis Biotherapeutics Announces Authorization of Phase IIb Clinical Study of Gene Therapy for AADC Deficiency

Aug 2, 2016

Agilis Biotherapeutics Announces FDA Orphan Drug Designation for the Treatment of Friedreich’s Ataxia (FA)

Jun 27, 2016

Agilis Biotherapeutics, First Gene Therapy Company Selected for NIH Therapeutics for Rare and Neglected Diseases Program

Mar 22, 2016

Agilis Biotherapeutics and T-TOP Clinical Research Enter into an Agreement for the Development of Gene Therapy Treatment of AADC Deficiency

Mar 14, 2016

Agilis Biotherapeutics Sponsors Inaugural Angelman Syndrome Biomarker and Outcome Measures Meeting

Feb 18, 2016

Agilis Biotherapeutics and Waisman Biomanufacturing Enter Into Exclusive Manufacturing Agreement for Friedreich’s Ataxia Gene Therapy

Jan 28, 2016

Agilis Biotherapeutics and National Taiwan University Enter into Worldwide, Exclusive License Agreement for the Gene Therapy Treatment of AADC Deficiency

Jan 25, 2016

Agilis Biotherapeutics Names Former Lundbeck Executive, Christopher J. Silber, MD, as Chief Medical Officer

Nov 19, 2015

Agilis Biotherapeutics Named as Top Company to Watch

Nov 4, 2015

Agilis Biotherapeutics Announces FDA Orphan Drug Designation for AGIL-AS for the Treatment of Angelman Syndrome

Sep 17, 2015

Agilis Biotherapeutics and the University of South Florida Enter into Worldwide, Exclusive License Agreement for the Treatment of Cognitive Disorders Using Reelin-Based Therapies

May 13, 2015

Agilis Biotherapeutics and the University of South Florida Enter Into Worldwide, Exclusive License Agreement for Angelman Syndrome Gene Therapy

Nov 24, 2014

Agilis Biotherapeutics Names Former Shire Executive Dr. Gregory Robinson as Chief Scientific Officer

Sep 10, 2014

Agilis Biotherapeutics Names Dr. Mark J. Pykett as President and Chief Executive Officer

Jun 5, 2014

Agilis Biotherapeutics Appoints Dr. Arthur Tzianabos to the Scientific Advisory Board

Jun 3, 2014

Dr. John Monahan, a Veteran in Biotechnology and Gene Therapy Companies, Joins the Scientific Advisory Board of Agilis Biotherapeutics

Mar 5, 2014

Dr. James J. Collins, a Pioneer in Synthetic Biology, Joins the Scientific Advisory Board of Agilis Biotherapeutics

Dec 31, 2013

George S. Zorich Named Chief Executive Officer of Agilis Biotherapeutics

Dec 31, 2013

Agilis Biotherapeutics and Intrexon to Pursue Transformative Therapies for Rare Genetic Disease

Google Analytics Alternative